Uncategorized
Valeant, EyeGate enter licensing agreement
Valeant Pharmaceuticals has entered into a licensing agreement with EyeGate Pharmaceuticals regarding the EyeGate II delivery system and EGP-437 combination product candidate for postoperative pain and inflammation, according to a press release from the companies. Through the agreement, Valeant will have worldwide commercial and manufacturing rights for the EyeGate II delivery system and EGP-437, while EyeGate will maintain development of the delivery system in the U.S. Valeant can develop the system outside of the U.S.